Inclusion Criteria:

          -  Written informed consent

          -  At least 18 years of age

          -  Eastern Cooperative Oncology Group Performance Status score of 0 or 1

          -  Availability of archived tumor tissue samples

          -  Has a left ventricular ejection fraction (LVEF) ≥50% by either an echocardiogram
             (ECHO) or multigated acquisition scan (MUGA) within 28 days before study start

          -  Has adequate organ function within 7 days before the start of study treatment

          -  Has an adequate treatment washout period prior to start of study treatment

          -  Male participants with female partners of childbearing potential and female
             participants of child-bearing potential must agree to use a highly effective form of
             contraception or avoid intercourse during and upon completion of the study and for at
             least 4 months (for males) and for at least 7 months (for females) after the last dose
             of study drug.

        Exclusion Criteria:

          -  Has had prior treatment with other CDH6-targeted agents

          -  Has had prior treatment with an ADC that consists of an exatecan derivative that is a
             topoisomerase I inhibitor (e.g., trastuzumab deruxtecan, DS-1062a, DS-7300a)

          -  Has history or current presence of CNS metastases except for participants who have
             completed radiotherapy or surgery ≥2 weeks before the start of treatment and have no
             evidence of disease progression in the CNS and no requirement for chronic
             corticosteroid therapy within 2 weeks before the start of treatment

          -  Has multiple primary malignancies, except adequately resected non-melanoma skin
             cancer, curatively treated in situ disease, or other solid tumors curatively treated,
             with no evidence of disease for ≥3 years)

          -  Has a history of myocardial infarction or unstable angina within 6 months before study
             treatment

          -  Has a medical history of symptomatic congestive heart failure (New York Heart
             Association classes II-IV) or a serious cardiac arrhythmia requiring treatment

          -  Lung-specific intercurrent clinically significant illnesses

          -  Has an uncontrolled infection requiring systemic therapy